Biomarin Pharmaceutical (BMRN) Cash & Equivalents Growth (3y) (2012 - 2026)

Biomarin Pharmaceutical (BMRN) Cash & Equivalents Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Biomarin Pharmaceutical 11.65 Bn 9.42 Bn 571.21 Mn 56.48%

Historic Data

Download Data
DateValue
Mar 31, 2026 56.48%
Dec 31, 2025 21.88%
Sep 30, 2025 17.97%
Jun 30, 2025 25.11%
Mar 31, 2025 20.10%
Dec 31, 2024 17.09%
Sep 30, 2024 3.05%
Jun 30, 2024 14.86%
Mar 31, 2024 3.83%
Dec 31, 2023 5.17%
Sep 30, 2023 -8.21%
Jun 30, 2023 -5.35%
Mar 31, 2023 6.77%
Dec 31, 2022 18.32%
Sep 30, 2022 21.63%
Jun 30, 2022 26.31%
Mar 31, 2022 18.44%
Dec 31, 2021 5.94%
Sep 30, 2021 -11.23%
Jun 30, 2021 14.50%